Alzheimer’s Setback Hits INmune Bio Stock, But FDA Hopes Remain

All NewsJune 30, 2025

INmune Bio’s Alzheimer’s drug XPro showed targeted benefits in patients with brain inflammation, but misses the main trial endpoint.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent